- Remove All
 Your shopping cart is currently empty Your shopping cart is currently empty
Neuropilin-1 (Npn-1, previously neuropilin; also CD304) is a 130 - 140 kDa type I transmembrane (TM) glycoprotein that regulates axon guidance and angiogenesis. Two homologues, Neuropilin-1 and Neuropilin-2, are identified. Neuropilin-1 binds to semaphorin 3A, The PLGF-2 isoform of PGF, The VEGF-165 isoform of VEGF and VEGF-B. Coexpression with KDR results in increased VEGF-165 binding to KDR as well as increased chemotaxis. It may regulate VEGF-induced angiogenesis. The soluble isoform 2 binds VEGF-165 and appears to inhibit its binding to cells. NRP1 expression is regulated in EC by tumor necrosis factor-alpha, the transcription factors dHAND and Ets-1, and vascular injury. NRP1 upregulation is positively correlated with the progression of various tumors.

| Pack Size | Price | Availability | Quantity | 
|---|---|---|---|
| 5 μg | $129 | 7-10 days | |
| 10 μg | $213 | 7-10 days | |
| 20 μg | $355 | 7-10 days | |
| 50 μg | $625 | 7-10 days | |
| 100 μg | $963 | 7-10 days | 
| Biological Activity | Immobilized Anti-Human NRP1 mAb at 2μg/ml (100 μl/well) can bind Human Neuropilin-1-Avi-His.  The ED50 of Human Neuropilin-1-Avi-His is 9.33 ng/ml. (Regularly tested) | 
| Description | Neuropilin-1 (Npn-1, previously neuropilin; also CD304) is a 130 - 140 kDa type I transmembrane (TM) glycoprotein that regulates axon guidance and angiogenesis. Two homologues, Neuropilin-1 and Neuropilin-2, are identified. Neuropilin-1 binds to semaphorin 3A, The PLGF-2 isoform of PGF, The VEGF-165 isoform of VEGF and VEGF-B. Coexpression with KDR results in increased VEGF-165 binding to KDR as well as increased chemotaxis. It may regulate VEGF-induced angiogenesis. The soluble isoform 2 binds VEGF-165 and appears to inhibit its binding to cells. NRP1 expression is regulated in EC by tumor necrosis factor-alpha, the transcription factors dHAND and Ets-1, and vascular injury. NRP1 upregulation is positively correlated with the progression of various tumors. | 
| Species | Human | 
| Expression System | HEK293 Cells | 
| Tag | C-Avi-6xHis | 
| Accession Number | AAH07533.1 | 
| Synonyms | VEGF165R,NRPNP1,NRP1,CD304,BDCA4 | 
| Amino Acid | Phe22-Lys644 | 
| Construction | Phe22-Lys644 | 
| Protein Purity | Greater than 95% as determined by reducing SDS-PAGE. (QC verified) | 
| Molecular Weight | 85-100 KDa (reducing condition) | 
| Endotoxin | < 0.1 ng/µg (1 EU/µg) as determined by LAL test. | 
| Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. | 
| Reconstitution | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. | 
| Stability & Storage | Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. | 
| Shipping | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. | 
| Research Background | Neuropilin-1 (Npn-1, previously neuropilin; also CD304) is a 130 - 140 kDa type I transmembrane (TM) glycoprotein that regulates axon guidance and angiogenesis. Two homologues, Neuropilin-1 and Neuropilin-2, are identified. Neuropilin-1 binds to semaphorin 3A, The PLGF-2 isoform of PGF, The VEGF-165 isoform of VEGF and VEGF-B. Coexpression with KDR results in increased VEGF-165 binding to KDR as well as increased chemotaxis. It may regulate VEGF-induced angiogenesis. The soluble isoform 2 binds VEGF-165 and appears to inhibit its binding to cells. NRP1 expression is regulated in EC by tumor necrosis factor-alpha, the transcription factors dHAND and Ets-1, and vascular injury. NRP1 upregulation is positively correlated with the progression of various tumors. | 

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.